logo-loader
viewBarratt Developments

Barratt boss steps down; finance chief to take charge

markclare2_5515209f8fee3.jpg

Barratt Developments (LON:BDEV) chief executive Mark Clare is stepping down after nine years in charge of the housebuilder.

Clare will hand over the reins to current finance director David Thomas, who will take charge at the start of July.

Chairman John Allan said Clare leaves a “tremendous legacy” having steered the firm through one of the most challenging periods in its history after the financial crash in 2008.

“Mark has led a very successful land investment strategy and realigned the business around its customers,” said Allan.

“He has also played an important role in the wider industry in terms of shaping housing policy and addressing the longer term challenges the sector faces.”

Recent interim profits from the firm were up by over 70%, well ahead of expectations. Shares have risen over 300% in the past five years to 540p.

Clare will remain with the group until the end of October 2015 to ensure an orderly handover to Thomas, who orchestrated a £720mln rights issue that saved the company shortly after he joined in 2009.

"In David Thomas, the Board is extremely pleased to have such a strong successor in place," Allan  added.

“Over the last six years David has played a key role in developing the Group's strategy, driving performance and embedding the disciplined approach that has served us so well.

Barratt shares were up 3p to 540p shortly after the announcements. 

Quick facts: Barratt Developments

Price: 652.6 GBX

LSE:BDEV
Market: LSE
Market Cap: £6.64 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Thrombo Therapeutics 'shovel-ready' for pivotal trial on its traumatic...

Thrombo Therapeutics Inc Dr Michael Chapman sat down with Proactive at the 2019 BIO Investor Forum.  The privately-held company is focused on treating traumatic injuries with its fast-acting diagnostic. Chapman indicated the company is 'shovel-ready' for a pivotal trial. 

32 minutes ago

RNS

Director/PDMR Shareholding

6 days, 7 hours ago

Result of AGM

6 days, 16 hours ago

Total Voting Rights

3 weeks, 1 day ago

Director/PDMR Shareholding

3 weeks, 2 days ago

Final Results

on 09/04/2019

Total Voting Rights

on 09/02/2019

2 min read